NASDAQ: TARA - Protara Therapeutics, Inc.

Yield per half year: +171.43%
Sector: Healthcare

Share chart Protara Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.

more details
The company is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-10-22
ISIN US74365U1079
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.protaratx.com
Цена ао 4.15
Change price per day: +0.1818% (5.5)
Change price per week: +2.23% (5.39)
Change price per month: +81.25% (3.04)
Change price per 3 month: +191.53% (1.89)
Change price per half year: +171.43% (2.03)
Change price per year: +193.87% (1.875)
Change price per 3 year: -18.01% (6.72)
Change price per 5 year: +1 627.27% (0.319)
Change price per 10 year: 0% (5.51)
Change price per year to date: +117.79% (2.53)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0.3035 10
P/E 0 0
EV/EBITDA 0.3093 10
Total: 5

Efficiency

Title Value Grade
ROA, % -51.19 0
ROE, % -59.16 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1263 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 184.68 10
Yield EPS, % 41.55 6
Total: 7.2
More

Institutions Volume Share, %
Opaleye Management Inc. 2692594 23.55
Vanguard Group Inc 427612 3.74
Boxer Capital, LLC 209227 1.83
Baker Brothers Advisors, LLC 199671 1.75
Ikarian Capital, LLC 188664 1.65
Privium Fund Management (UK) Ltd 119730 1.05
Renaissance Technologies, LLC 113300 0.99
Geode Capital Management, LLC 78518 0.69
Bridgeway Capital Management, Inc. 64000 0.56
Citadel Advisors Llc 38035 0.33

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00906 17.09 1.54048



Head Job title Payment Year of birth
Mr. Jesse Shefferman Co-founder, CEO, President & Director 1.02M 1972 (53 years)
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Co-Founder, Senior VP & Chief Scientific Operations Officer 694.16k 1981 (44 years)
Mr. Patrick Fabbio M.B.A. Chief Financial Officer 696.62k 1968 (57 years)
Ms. Hannah Fry VP, Principal Accounting Officer & Controller N/A 1991 (34 years)
Ms. Mary J. Grendell General Counsel & Corporate Secretary N/A
Ms. Justine O'Malley Senior Vice President of Investor Relations & Corporate Affairs

Address: United States, New York. NY, 345 Park Avenue South - open in Google maps, open in Yandex maps
Website: https://www.protaratx.com